JP2002505878A - 前立腺組織由来のヒト核酸配列 - Google Patents
前立腺組織由来のヒト核酸配列Info
- Publication number
- JP2002505878A JP2002505878A JP2000535742A JP2000535742A JP2002505878A JP 2002505878 A JP2002505878 A JP 2002505878A JP 2000535742 A JP2000535742 A JP 2000535742A JP 2000535742 A JP2000535742 A JP 2000535742A JP 2002505878 A JP2002505878 A JP 2002505878A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- seq
- sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 65
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 12
- 210000002307 prostate Anatomy 0.000 title claims abstract description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 24
- 229920001184 polypeptide Polymers 0.000 claims abstract description 23
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 9
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 9
- 230000014509 gene expression Effects 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 13
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 230000014107 chromosome localization Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 238000002823 phage display Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 description 30
- 108091060211 Expressed sequence tag Proteins 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 239000013598 vector Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101100282116 Candida albicans (strain SC5314 / ATCC MYA-2876) GAP4 gene Proteins 0.000 description 2
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100033040 Carbonic anhydrase 12 Human genes 0.000 description 1
- 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 101000867855 Homo sapiens Carbonic anhydrase 12 Proteins 0.000 description 1
- 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19811194.0 | 1998-03-10 | ||
| DE19811194A DE19811194A1 (de) | 1998-03-10 | 1998-03-10 | Menschliche Nukleinsäuresequenzen aus Prostatagewebe |
| PCT/DE1999/000722 WO1999046375A2 (de) | 1998-03-10 | 1999-03-09 | Menschliche nukleinsäuresequenzen aus prostatagewebe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002505878A true JP2002505878A (ja) | 2002-02-26 |
Family
ID=7860959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000535742A Pending JP2002505878A (ja) | 1998-03-10 | 1999-03-09 | 前立腺組織由来のヒト核酸配列 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1068318A2 (de) |
| JP (1) | JP2002505878A (de) |
| DE (1) | DE19811194A1 (de) |
| WO (1) | WO1999046375A2 (de) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537814A (ja) * | 1999-03-04 | 2002-11-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒスチジン・プロテイン・ホスファターゼ |
| WO2004090098A3 (en) * | 2003-04-01 | 2006-02-16 | Univ California | Phosphatase regulation of nucleic acid transcription |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073454A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030059780A1 (en) | 1997-06-16 | 2003-03-27 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7264801B2 (en) | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| WO2001068857A2 (en) * | 2000-03-15 | 2001-09-20 | Millennium Pharmaceuticals, Inc. | 18615 and 48003, human ion channels and uses therefor |
| MXPA03003745A (es) * | 2000-10-30 | 2003-10-15 | Bristol Myers Squibb Co | Polinucleotido que codifica una proteina derivada del linfocito t humano activado, relacionado con la enzima de conjugacion de ubiquitina. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998004689A1 (en) * | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US5861248A (en) * | 1996-03-29 | 1999-01-19 | Urocor, Inc. | Biomarkers for detection of prostate cancer |
| EP1000146B1 (de) * | 1997-08-01 | 2006-08-30 | Serono Genetics Institute S.A. | 5' ests für proteine, die nicht gewebespezifisch sind |
-
1998
- 1998-03-10 DE DE19811194A patent/DE19811194A1/de not_active Withdrawn
-
1999
- 1999-03-09 EP EP99920546A patent/EP1068318A2/de not_active Ceased
- 1999-03-09 WO PCT/DE1999/000722 patent/WO1999046375A2/de not_active Application Discontinuation
- 1999-03-09 JP JP2000535742A patent/JP2002505878A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537814A (ja) * | 1999-03-04 | 2002-11-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒスチジン・プロテイン・ホスファターゼ |
| WO2004090098A3 (en) * | 2003-04-01 | 2006-02-16 | Univ California | Phosphatase regulation of nucleic acid transcription |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999046375A2 (de) | 1999-09-16 |
| WO1999046375A3 (de) | 2000-07-06 |
| EP1068318A2 (de) | 2001-01-17 |
| DE19811194A1 (de) | 1999-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002512795A (ja) | 膵臓癌組織由来ヒト核酸配列 | |
| JP2002511252A (ja) | 卵巣腫瘍組織からのヒト核酸配列 | |
| JP2002532055A (ja) | 子宮内膜腫瘍組織からのヒト核酸配列 | |
| JP2002506643A (ja) | 乳房腫瘍組織に由来するヒト核酸配列 | |
| JP2001512013A (ja) | 前立腺に発現される分泌タンパク質の５’ｅｓｔ | |
| JP2001269182A (ja) | 配列タグおよびコードされたヒトタンパク質 | |
| JP2001512011A (ja) | 組織非特異的分泌タンパク質の５’ｅｓｔ | |
| JP2001512015A (ja) | 脳における分泌タンパク質の５’ｅｓｔ | |
| JP2001512016A (ja) | 筋肉およびその他中胚葉組織中で発現される分泌タンパク質の５’ｅｓｔ | |
| JP2001512012A (ja) | 精巣およびその他の組織で発現する分泌タンパク質の５’ｅｓｔ | |
| JP2002530077A (ja) | 炎症関連遺伝子 | |
| JP2001512014A (ja) | 脳組織から同定された分泌タンパク質の５’ｅｓｔ | |
| JP2002510486A (ja) | 正常卵巣組織からのヒト核酸配列 | |
| JP2002531052A (ja) | 正常膀胱組織由来ヒト核酸配列 | |
| JP2001512005A (ja) | 内胚葉において発現する分泌タンパク質の５’ｅｓｔ | |
| US5846778A (en) | Human map kinase homolog | |
| JP2002525024A (ja) | 種々の組織中で発現される分泌タンパク質の５’ｅｓｔ | |
| JP2002505877A (ja) | 前立腺腫瘍組織由来のヒト核酸配列 | |
| JP2002536995A (ja) | 結腸の疾患に関連する遺伝子 | |
| JP2002512017A (ja) | 正常子宮組織からのヒト核酸配列 | |
| JP2002512023A (ja) | 膀胱癌組織由来ヒト核酸配列 | |
| JP2002505878A (ja) | 前立腺組織由来のヒト核酸配列 | |
| HUP0400698A2 (hu) | Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA) | |
| KR100270348B1 (ko) | 전사인자 에이피알에프 | |
| JP2002506639A (ja) | ヒト正常乳房組織からのヒト核酸配列 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050208 |